HomePipelinePNB-001

Front-runner

PNB-001

Clinical · Phase 1 and Phase 2 completed

The front runner of the portfolio.
Developed from immune-mediated
Inflammatory research, PNB-001 is in Phase 3 for Covid-19 and has completed Phase 2 in Ulcerative Colitis & Crohn's Disease

Stage of development

  • PNB-001

    COVID-19 Lung InflammationCCK ligand, lymphokine

  • PNB-001

    Ulcerative ColitisCCK ligand, lymphokine, T-cell activation

  • PNB-001

    Crohn's DiseaseCCK ligand, lymphokine, T-cell activation

  • PNB-001

    Type 2 DiabetesCCK-mediated blood glucose reduction; restoration of pancreatic cells

  • PNB-001

    DementiaCCK-mediated release of acetylcholine (ACh)

Graph of the stage of development of each PNB-001 programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Target and mechanism
CCK-A agonist with CCK-B (CCK2/gastrin) antagonist properties, described by the company as first in class. Acts as a lymphokine, raising CD4 and CD8 T cells.
Key findings

Phase 1 (single and multiple ascending dose) completed in 74 healthy subjects across 25–1,500 mg; target plasma concentrations were reached.

In Phase 2 studies in COVID-19 and IBD, CD4 helper and CD8 cytotoxic T-cell counts rose into the healthy range, which the company describes as the drug's established mode of action.

Type 2 Diabetes (preclinical): PNB-001 lowered blood glucose by releasing insulin, with insulin release increased by more than 400% in diabetic animals and an effect lasting more than 10 hours in the oral glucose tolerance test. The company describes it as the first small-molecule, non-peptide incretin.

Dementia (preclinical): CCK-mediated acetylcholine release improved learning and memory in rodent water-maze studies, with no cardiotoxicity seen.

Development

Synthesis established under non-GMP and GMP conditions and optimised to multi-kilogram scale; 50 mg and 100 mg hard gelatin capsules manufactured under GMP.

GLP regulatory toxicology and safety pharmacology (cardiac, renal, respiratory, neuro) in rats and dogs, per ICH guidelines. No inhibition of CYP3A4, CYP2C9 or CYP1A2 up to 10 µM, or CYP2C19 up to 3 µM.

Intellectual property
Patents filed in the US, Europe and rest of world; USPTO patent issued 28 December 2014. Composition-of-matter protection to 2037; an immune-use patent extends protection to 2041.
PNB-001 clinical trials

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.